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Abstract: Magnetic hyperthermia – a potential cancer treatment in which superparamagnetic 
iron oxide nanoparticles (SPIONs) are made to resonantly respond to an alternating magnetic 
field (AMF) and thereby produce heat – is of significant current interest. We have previously 
shown that mesenchymal stem cells (MSCs) can be labeled with SPIONs with no effect on 
cell proliferation or survival and that within an hour of systemic administration, they migrate 
to and integrate into tumors in vivo. Here, we report on some longer term (up to 3 weeks) 
post-integration characteristics of magnetically labeled human MSCs in an immunocompro-
mized mouse model. We initially assessed how the size and coating of SPIONs dictated the 
loading capacity and cellular heating of MSCs. Ferucarbotran® was the best of those tested, 
having the best like-for-like heating capability and being the only one to retain that capabil-
ity after cell internalization. A mouse model was created by subcutaneous flank injection of 
a combination of 0.5 million Ferucarbotran-loaded MSCs and 1.0 million OVCAR-3 ovarian 
tumor cells. After 2 weeks, the tumors reached ~100 µL in volume and then entered a rapid 
growth phase over the third week to reach ~300 µL. In the control mice that received no AMF 
treatment, magnetic resonance imaging (MRI) data showed that the labeled MSCs were both 
incorporated into and retained within the tumors over the entire 3-week period. In the AMF-
treated mice, heat increases of ~4°C were observed during the first application, after which 
MRI indicated a loss of negative contrast, suggesting that the MSCs had died and been cleared 
from the tumor. This post-AMF removal of cells was confirmed by histological examination 
and also by a reduced level of subsequent magnetic heating effect. Despite this evidence for 
an AMF-elicited response in the SPION-loaded MSCs, and in contrast to previous reports on 
tumor remission in immunocompetent mouse models, in this case, no significant differences 
were measured regarding the overall tumor size or growth characteristics. We discuss the 
implications of these results on the clinical delivery of hyperthermia therapy to tumors and 
on the possibility that a preferred therapeutic route may involve AMF as an adjuvant to an 
autologous immune response.
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Introduction
Hyperthermia .43°C is capable of inducing cell death both directly, by inducing 
apoptosis, and indirectly, by protein denaturation or DNA damage.1 Hyperthermia has 
also been shown to adversely affect the fluidity and stability of cellular membranes, the 
function of transmembrane transport proteins, and cell surface receptor expression.1 
Notably, tumor cells are more sensitive to sudden increases in temperature than normal 
cells, making hyperthermia an attractive therapeutic tool.2
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Hyperthermia in superparamagnetic iron oxide nano-
particle (SPION)-laden tumors can be induced by the 
presence of a rapidly alternating magnetic field (AMF).3 
SPIONs are nanosized particles with a diameter typically 
ranging between 50 and 100 nm. They consist of one or more 
crystalline cores of superparamagnetic iron (Fe3+) oxide, which 
are typically 5–10 nm in diameter, surrounded by a biocompat-
ible coating such as starch, dextran, carboxydextran, or citric 
acid. SPION cores are small enough that the net magnetocrys-
talline anisotropy energy, which is proportional to the volume 
of the particle, is comparable to the environmental thermal 
bath energy at, or below, room temperature. This leads to ther-
mally induced reversals of the net magnetization, which is the 
phenomenon of superparamagnetism. The production of heat 
can be generated through magnetic hysteretic and relaxation 
losses (Néel relaxation) as well as through physical rotation 
(Brownian relaxation) under the influence of an AMF.4,5
SPION-induced hyperthermia within tumors has been 
achieved previously but has relied on direct injection of 
milligram concentrations of iron into superficial tumors,6–11 
which limits the approach to only the accessible superficial 
tumors, such as melanomas. Although functionalization 
of SPIONs with antibodies,12–15 antibody fragments,16,17 or 
peptides18–21 has been used to enhance the accumulation 
of SPIONs in tumors, there have been problems with 
pharmacokinetics, immunogenicity, and toxicity.
We, and others, have shown that mesenchymal stem cells 
(MSCs) migrate to and incorporate into tumors.22–26 We there-
fore propose the possibility of using MSCs as cell carriers to 
deliver SPIONs to multiple, difficult-to-reach sites, as in the 
case of a metastatic malignant disease. However, this presup-
poses that the heating character of SPIONs within the MSCs 
is retained after internalization, as well as over a prolonged 
period of time that would be needed for cell targeting prior 
to hyperthermia treatment. Retention of the heating potential 
may also be considered to be a necessary safety element for 
any potential therapeutic interventions based on magnetic field 
hyperthermia. For instance, it may well be difficult to prove, a 
priori, that an introduced MSC might not, on arrival at a tumor 
site, itself differentiate into a tumor cell – thereby potentially 
exacerbating rather than improving the situation. Although our 
previous data suggest that normal MSCs do not affect tumor 
growth in an orthotopic lung tumor model,27 in such a case, 
the ability to kill by hyperthermia, the introduced MSC might 
well be seen to be an imperative fail-safe characteristic.
MSCs have been shown to actively take up and retain 
SPIONs from a loaded cell culture medium.22 Although there 
have been reports in the literature of dose-dependent effects 
on the health of MSCs,28,29 our group and others have shown 
that it is possible to achieve SPION labeling at a level that 
does not affect the survival, proliferation, or differentiation 
potential of MSCs.22,30 Furthermore, we have demonstrated 
that MSCs maintain their migratory capacity to pulmonary 
metastases after SPION labeling, with subsequent infiltration 
of the tumor.22 We have also shown that SPION-loaded MSCs 
can be targeted to specific areas via magnetic targeting.31–33 
We have therefore hypothesized that the tumor-targeting 
potential of MSCs could be exploited to deliver SPIONs 
to tumors for subsequent hyperthermia therapy. However, 
we have not previously established whether SPIONs within 
the MSCs degrade or otherwise lose their heating potential 
during the period between their introduction into the body 
and their subsequent arrival at the tumor. The present study 
is designed to address this question by exploring the time-
dependent heating characteristics of SPION-loaded MSCs 
in a long-term, viable, animal model.
The present study defines the contribution of size and 
chemical coating of six different SPIONs on MSC uptake and 
AMF-induced hyperthermia. We assess the role of cellular 
internalization of each SPION on the subsequent level of AMF-
induced hyperthermia and choose the SPION with the most 
suitable characteristics. We then assess the therapeutic pos-
sibility of using SPION-loaded MSCs as a delivery vector for 
hyperthermia therapy in an in vivo subcutaneous tumor model 
in immunosuppressed nude mice. The immunosuppressed 
model is chosen for two reasons: 1) to assess the physical effect 
of heating on cell death and tumor volume rather than com-
bine (and possibly confuse) the outcomes with downstream 
mediators such as immune responses and 2) to enable accurate 
measurements of both tumor size, via external calipers, and 
heat generation, via skin thermocamera imaging.
Materials and methods
superparamagnetic iron oxide 
nanoparticles
FluidMAG-CT (polymer matrix: citric acid), 50 nm and 
100 nm; FluidMAG-CMX (carboxymethyldextran), 50 nm; 
FluidMAG-DX (dextran), 50 nm; and FluidMAG-D (starch), 
50 nm, nanoparticles were obtained from Chemicell (Berlin, 
Germany). Ferucarbotran® (carboxydextran) 60 nm-sized 
particles were obtained from Meito Sangyo Co., Ltd. 
(Nagoya, Japan).
The hydrodynamic diameter and ζ-potential of each iron 
oxide were determined by using a Nanosizer ZS90 (Malvern 
Instruments, Malvern, UK). A Quantum Design supercon-
ducting quantum interference device (SQUID) VSM magne-
tometer (Quantum Design Inc., San Diego, CA, USA) was 
used to assess the magnetic properties of the nanoparticles.
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One milliliter solutions of 1 mg/mL were made up in 
water for both FluidMAG and Ferucarbotran to assess 
particle-heating capacities.
Tissue culture
Human MSCs were purchased from the Tulane Centre for 
Gene Therapy, New Orleans, LA, USA, and were cultured 
in alpha minimum essential media (α-MEM) supplemented 
with 16% heat-inactivated fetal bovine serum (FBS), 
l-glutamine (4 mM), penicillin G (50 U/mL), and streptomy-
cin (50 µg/mL), all of which were purchased from Thermo 
Fisher Scientific (Waltham, MA, USA).
Human OVCAR-3 ovarian carcinoma cancer cells were 
obtained from the Metabolic and Molecular Imaging Group, 
MRC Clinical Sciences Centre, Imperial College, London 
(originally from the ATCC® HTB-161™). Cells were cul-
tured in RPMI 1640 media (Thermo Fisher Scientific) supple-
mented with 10% FBS, l-glutamine (4 mM), penicillin G 
(50 U/mL), and streptomycin (50 µg/mL).
All cells were grown in T175 flasks (Thermo Fisher 
Scientific) in a humidified incubator at 37°C with 95% air 
and 5% CO
2
. The cell lines used within this study have been 
purchased from known cell providers, and are an expansion 
of the original primary cell culture. These cell lines are 
therefore not considered relevant material under the Human 
Tissue Act and do not require ethics approval.
sPION labeling, phenotyping, visualization, 
and iron quantification of MSCs
MSCs were incubated overnight (12 hours) with 0.5 mg/mL 
of SPION solution in 20 mL normal α-MEM cell culture 
media. Following this, they were washed multiple times with 
10 mL phosphate-buffered saline (PBS), until excess SPIONs 
had been removed. Adipogenic and osteogenic differentia-
tion of MSCs was performed as previously described.34,35 
Prussian blue staining of fixed cells (4% paraformaldehyde) 
was performed using freshly prepared 2% potassium fer-
rocyanide and 2% hydrochloric acid (Sigma-Aldrich, Co., 
St Louis, MO, USA) and incubated for 10 minutes. Images 
were taken using a Zeiss Axiovert S100 microscope (Carl 
Zeiss Meditec AG, Jena, Germany) with QCapture software 
(QImaging, Surrey, BC, Canada).
Cells for iron quantification or in vivo injection were 
trypsinized and counted, and an aliquot of 5×105 cells were 
pelleted for in vitro heating and magnetometry analysis.22 
Room temperature SQUID magnetization analysis was used 
to measure the amount of iron oxide. The samples were 
saturated in a field of 7 T and the moment was measured. 
The saturated moment was then compared with a sample of 
known iron oxide mass in order to quantify the iron oxide 
cell loading mass. The remainder was resuspended in PBS 
at a concentration of 1×106 cells/mL to be stained with 
CellTracker™ CM-DiI (Thermo Fisher Scientific) for in vivo 
injection. A total of 5 µM DiI (5 µL) was added and left for 
15 minutes on ice prior to washing.
animals and tumor model
All animal studies were approved by the University College 
London Biological Services Ethical Review Committee 
and licensed under the UK Home Office regulations and 
the Guidance for the Operation of Animals (Scientific Pro-
cedures) Act 1986 (Home Office, London, UK). Animal 
weights and tumor monitoring were recorded every 2 days. 
Magnetic resonance imaging (MRI) scanning was carried 
out with animal monitoring equipment. All procedures 
were carried out under breathing anesthesia, and all mice 
were sacrificed by schedule 1; 1×106 OVCAR-3 cells were 
mixed with 5×105 SPION-labeled MSCs in 100 µL serum-
free RPMI media and injected subcutaneously into the 
flanks of 6–8-week-old female immunosuppressed Balb/c 
nu/nu mice (n=4, two not heated and two heated – MSCs 
labeled with Ferucarbotran). Once palpable, tumors were 
measured in three orthogonal dimensions using calipers. 
Tumor volumes were estimated assuming an ellipsoid shape 
using the formula: 
 Volume = length × width × depth × π/6. 
Magnetic resonance imaging
All images were acquired on a 9.4 T horizontal bore Agilent 
NMR system (Agilent, Palo Alto, CA, USA) using a 39 mm 
radio frequency coil (RAPID Biomedical GmbH, Wurzberg, 
Germany). On days 14, 18, and 21, mice were anesthetized 
with an isoflurane/oxygen mixture using a warm air blower 
to maintain the body core temperature at 37°C. A fast 
spin-echo multislice sequence using the following parameters 
was used to evaluate the presence of SPIONs within the 
tumor; repetition time =1,500 ms, echo time =10 ms, field 
of view =40×40 mm2, averages: one, matrix size: 128×128, 
12 contiguous 2 mm thick transverse slices covering the 
whole lower abdomen were used to ensure complete tumor 
coverage.
Magnetic alternating current hyperthermia 
device
The magnetic alternating current hyperthermia (MACH) 
system (Resonant Circuits Limited, London, UK) generated 
an AMF of 10 mT at 1.05 MHz in both a three-turn copper 
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solenoid coil (3.5 cm diameter for mice) and a six-turn cop-
per solenoid coil (2.7 cm diameter for Eppendorf phantoms). 
Cold water was run through the center of the copper to prevent 
ohmic heating of the coil, so that this did not transfer any 
environmental heat to any object placed inside the coil.
SPION Eppendorf phantom preparations were typically 
heated for 20 minutes from room temperature to assess 
the heating capacity of the particles at set concentrations. 
Thermal plateaus were reached in this time. MSCs labeled 
with SPIONs in ~100 µL total volume (cells plus residual 
fluid) were also heated from room temperature until they 
reached a plateau temperature.
On days 15, 17, 19, and 20, mice were anesthetized with 
an isofluorane/oxygen mixture and received either 20 minutes 
of hyperthermia therapy or 20 minutes of sham therapy 
with the AMF switched off. Treatment was performed in 
a thermostat-regulated warming cabinet (MediHeat, Peco 
Services, Cumbria, UK), with the inside temperature main-
tained at 37°C, to keep the core mouse temperature stable.
A Luxtron m3300 fiber-optic thermometry system was 
used to measure the temperature changes in vitro and the core 
and surface tumor temperature changes in vivo (Luxtron Co, 
Santa Clara, CA, USA). TrueTemp™ software (Luxtron Co) 
was used to acquire temperature data over each time course. 
For the final in vivo treatment session, an infrared thermal 
imaging camera (InfraTec VarioCAM® hr research 780) with 
IRBIS 3 software (InfraTec, Dresden, Germany) was also 
used to monitor the temperature of the tumor to compare the 
fiber-optic data recordings. The core temperature was then 
used to correct for any heating that may have been caused by 
alterations in body temperature due to the warming box.
histology
After the final MRI, the mice were sacrificed and tumors 
removed and fixed in 4% formalin. Tumors were processed 
and embedded in paraffin wax blocks and sectioned in 3 µm 
slices. Adjacent slices from each tumor were dewaxed and 
rehydrated with water and stained with hematoxylin and eosin 
(H&E) (Sigma-Aldrich Co.) and Perl’s Prussian blue for 
iron or counterstained with 4′,6-diamidino-2-phenylindole 
(DAPI; Sigma-Aldrich Co.) for HSP70 immunohistochem-
istry and DiI immunofluorescence.
H&E sections were incubated with hematoxylin solution 
for 1 minute and then in freshly prepared eosin Y for 
30 seconds. Perl’s sections were incubated in freshly prepared 
2% potassium ferrocyanide and 2% hydrochloric acid, as for 
fixed cells, for 10 minutes and then counterstained with 0.1% 
nuclear fast red (Sigma-Aldrich Co.) for 5 minutes. HSP70 
immunohistochemical slides were submitted to antigen 
retrieval by two, 5-minute cycles in boiling 10 mM sodium 
citrate in a microwave oven. The endogenous peroxidase 
activity was blocked with 3% H
2
O
2
 in PBS. For the detection 
of HSP70, the slides were incubated for 1 hour with mono-
clonal antibody sc-1060 (Santa Cruz Biotechnology Inc., 
Dallas, TX, USA) at a 1:100 dilution at room temperature. 
Biotinylated secondary antibody and avidin–biotin complex 
and 3,39-diaminobenzidine (Vectastain ABC Kit – Vector 
Laboratories, Burlingame, CA) were applied for visualization 
of the immunoreaction. Slides were counterstained with hema-
toxylin. Omission of the primary antibody was considered as 
a negative control. Histopathological alterations were assessed 
on H&E-stained sections. Sections were then dehydrated 
with alcohol and passed through histoclear (Thermo Fisher 
Scientific) and mounted with DPX (VWR, Poole, UK).
DiI sections were incubated with 300 nM DAPI and 
mounted using Vectashield mounting media (Vector, 
Peterborough, UK). Images were obtained using an Olympus 
BX40 microscope (Olympus Corporation, Tokyo, Japan) 
with QCapture software. Composite images of whole tumors 
were made from multiple single 100× images using Adobe 
Photoshop CS (Adobe Systems Incorporated, San Jose, CA, 
USA). Random slices throughout the tumors were then used 
to obtain the percentage area of both Perl’s and DiI staining 
using ImageJ software.36
Results
Msc endocytosis of sPION is dependent 
on particle coating
Our first aim was to evaluate the uptake of the six different 
SPIONs within MSCs. The chosen SPIONs had a range 
of synthetic coatings with and without functional groups. 
FluidMAG SPIONs were supplied with a range of particle 
coatings, citric acid (CT), caroboxymethyldextran (CMX), 
dextran (DX), and starch (D). We compared cellular uptake of 
the different coated FluidMAG particles and evaluated them 
against the carboxydextran-coated Ferucarbotran. SQUID 
measurements demonstrated FluidMAG-CT to have the 
highest uptake in cells with a maximal uptake of 250 pg/cell 
(Figure 1A). The hydrodynamic diameter of FluidMAG-CT 
(50 nm) was 75 nm (slightly larger than the 50 nm specified) 
and the ζ-potential was −52 mV, which reflects the nega-
tive charge of the functional carboxyl groups (COOH) 
on the surface. When a carboxyl group is deprotonated, a 
carboxylate anion is formed giving the particle an overall 
negative charge, and it is this charge that aids the uptake 
of the particle across the cell wall.37,38 The hydrodynamic 
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diameter of Ferucarbotran particles was 77 nm and the 
ζ-potential was −23 mV. Ferucarbotran also has carboxyl 
groups present,39 but to a lesser degree, and this particle 
showed an intermediate uptake of ~60 pg/cell (Figure 1A). 
Particles that were either neutral in charge or did not have 
reactive functional groups (such as dextran- and starch-coated 
particles) showed little uptake into cells (Figure 1A). Uptake 
of iron within the MSCs does not affect their differentiation 
potential in vitro (Figure 1B).
aMF-induced sPION heating is dependent 
on particle size
FluidMAG-CT particles were obtained in two particle 
sizes, 50 and 100 nm, and the influence of particle size 
on heating was evaluated. Representative heating changes 
from baseline room temperature for 1 mg/mL Ferucar-
botran (60 nm) and FluidMAG-CT, 50 and 100 nm-sized 
particles, are shown in Figure 1C. Ferucarbotran exhibited 
the highest heating capacity with a maximal increase 
in temperature of 18.5°C from baseline temperature 
(Figure 1C). The FluidMAG-CT 50 nm particle exhibited 
a temperature increase from the baseline of 13.1°C, while 
the FluidMAG-CT 100 nm particle showed the lowest tem-
perature rise at 10.6°C (Figure 1C). This demonstrates that 
particle size significantly affects AMF-induced heating for 
FluidMAG-CT. The 100 nm FluidMAG-CT particle was 
not tested further.
The heating curves were further analyzed with respect 
to the intrinsic loss parameters (ILPs) of the particles.40 
Following recommended analytical methods,41 the 
Figure 1 sPION uptake in Mscs and their corresponding magnetic heating characteristics.
Notes: (A) sQUID measurements of the concentration of iron oxide per mesenchymal stem cell (Msc) after overnight incubation of 0.5 mg/ml of FluidMag-cT (citric 
acid – 50 nm), FluidMag-cMX (carboxylmethyldextran), FluidMag-DX (dextran), FluidMag-D (starch), and Ferucarbotran (carboxydextran). (B) Mscs take up sPIONs 
without affecting their phenotype; (i) Mscs in culture; (ii) Perl’s Prussian blue staining of Mscs after overnight culture with Ferucarbotran nanoparticles; (iii) differentiation 
to osteoblasts, alizarin red s staining; (iv) differentiation to adipocytes, Oil red O staining. (C) Representative fiber-optic thermometry measurements of Ferucarbotran and 
FluidMag-cT (50 nm- and 100 nm-sized sPIO particles) at 1 mg/ml. (D) Representative fiber-optic thermometry measurements of cell heating of a 5×105 Msc pellet after 
overnight incubation of 0.5 mg/ml of FluidMag-cT 50 nm or Ferucarbotran (representative of three experiments).
Abbreviations: sQUID, superconducting quantum interference device; sPION, superparamagnetic iron oxide nanoparticle; sec, seconds.
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data yielded estimates ILPs of 2.4±0.1 nH m2 kg−1 for 
Ferucarbotran and 2.1±0.1 nH m2 kg−1 for the FluidMAG-CT 
50 nm particle.
sPION retention of aMF-induced heating 
properties after Msc endocytosis
The heating capabilities of both the FluidMAG-CT (50 nm) 
and Ferucarbotran SPIONs were tested using a pellet of 
5×105 SPION-labeled MSCs. Despite the fourfold increase 
in SPION concentration per cell in FluidMAG-CT-labeled 
cells (Figure 1A), Ferucarbotran still exhibited a greater rise 
in temperature by 5.9°C compared to 4.1°C (Figure 1D). It is 
notable that the concentration of Ferucarbotran in the cell 
pellet (60 pg/cell for 5×105 cells in a volume of 100 µL) cor-
responded to ~300 µg/mL and that the observed temperature 
rise was ~30% of the value achieved in the 1 mg/mL Ferucar-
botran phantom. This suggests that the heating mechanism is 
the same for Ferucarbotran SPIONs internalized within the 
MSCs, as it is in the water-based fluid.
The superior heating characteristics of Ferucarbotran are 
further exemplified by contrast with the performance of the 
FluidMAG-CT. The concentration of the latter was higher 
at ~1.2 mg/mL (250 pg/cell for 5×105 cells in a volume of 
100 µL), but the cells showed a markedly reduced heating 
curve compared to that of the 1 mg/mL phantom, suggest-
ing breakdown or degradation of the particles upon cell 
internalization. Ferucarbotran was therefore determined to 
be the superior heating particle for this application and was 
taken into the in vivo studies.
A final aspect is that the heating curves observed in the 
Ferucarbotran-loaded MSC pellets exhibited an unexpected 
two-step characteristic (Figure 1D). Despite careful scrutiny, 
we were not able to unambiguously determine the origin of 
this behavior, and it remains unexplained. One possibility 
is that it was related to a thermally induced change in the 
evaporation behavior of the sample.
aMF application to tumors containing 
sPION-loaded Mscs shows macroscopic 
heating and cell necrosis
Subcutaneous tumors were initiated by coinjecting 1 million 
OVCAR-3 cancer cells with 0.5 million MSCs containing 
60 pg/cell Ferucarbotran SPIONs. At day 14, the tumors 
measured ~100 mm3 (~100 µL). Thereafter, they entered a 
rapid growth phase, growing up to 300 mm3 (~300 µL) by 
day 22. Our previous study demonstrates that while there is 
expansion of the tumor cell population, the MSC population 
shows no detectable proliferation but maintains viability.22 
After 14 days of growth, tumors were assessed by MRI 
and then subjected to two rounds of AMF heating (days 15 
and 17). Tumors were reimaged on day 18, followed by 
two additional rounds of AMF heating (days 19 and 21), 
and a final MRI image (day 22) was taken before sacrifice 
(Figure 2A).
MRI of the OVCAR-3 tumors performed on day 14 
(before any AMF heating) showed complete signal loss 
throughout the whole tumor, indicating no loss of SPIONs 
from the cells, despite being within the tumor for 2 weeks 
(Figure 2B). This hypointensity artifact in the MRI data 
is an effect of superparamagnetism of the particles, which 
are magnetically saturated within the scanner, leading to a 
locally perturbed magnetic field around the particle and a 
subsequent loss of measurable signal. At the day 15 of AMF 
hyperthermia treatment, fiber-optic thermometry readings 
and thermoimaging indicated an AMF-induced heat increase 
of 4.3°C after application for 20 minutes – a surface tem-
perature of 41.5°C (Figure 2C and D). On repeat heating on 
days 17 and 19, the fiber-optic thermometry values gradually 
fell, until on the fourth and final heating (day 21), and the 
temperature after 20 minutes of AMF application was close 
to that of the nonheated control (Figure 2D).
MRI performed at day 22 demonstrated signal recovery 
in the heated OVCAR-3 tumors, compared to the nonheated 
tumors. This signal recovery likely indicates a loss of SPIONs 
within these tumors from MSC death and subsequent iron 
removal from the tumor (Figure 2B). No significant dif-
ferences in tumor size or growth were noted for the heated 
tumors compared to the nonheated controls throughout the 
study (Figure 2E).
hyperthermia treatment results in 
reduced content of both Mscs and 
sPIONs within tumors
While hyperthermia treatment did not affect tumor growth, the 
signal recovery seen on MRI at day 22 in the heated tumors 
suggested the loss of iron oxide. We confirmed histologically 
that OVCAR-3 tumors receiving AMF hyperthermia therapy 
had significantly less Perl’s Prussian blue staining (P,0.01) 
and significantly reduced DiI staining compared to that in the 
nonheated tumors (P,0.01). This indicates the loss of both 
iron and MSCs from the tumors (Figure 3A and B), consistent 
with MSC death due to heating and subsequent clearance from 
the tumor tissue. In the nonheated tumors, Perl’s staining 
suggested that MSCs were not evenly distributed throughout 
the tumor and that instead the MSCs tended to be situated in 
viable tumor areas, namely, near the periphery.
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A corollary of the observation of reduced Perl’s and 
DiI staining in the heated tumors, and of our interpretation 
of this as being the result of AMF-induced MSC death and 
subsequent clearance, is the implication that the tumor 
environment is one that allows active macrophage infiltra-
tion and trafficking. If this is the case, then it may be argued 
that macrophage clearance would apply also to any dead 
cells within the tumor – in which case, the observation of 
sustained Perl’s and DiI staining in the nonheated tumor tis-
sues may be taken as indirect evidence that in the absence 
of AMF treatment, the SPION-loaded MSCs remain viable 
and active within the tissue.
HSP70 staining showed no differences from controls, 
which may be due to the transient expression of HSP70 that 
would have been at its highest directly after the first and second 
AMF treatment 4 days prior to tumor removal.42 However, 
HSP70 staining could also have been confounded by the 
locality of the iron particles to any peroxidase staining. How-
ever, subsequent staining with a Texas Red fluorescent second-
ary antibody (sc-3919, Santa Cruz Biotechnology) also did not 
show staining above that of controls (data not shown).
Discussion
We have shown the potential of MSC delivery of SPIONs 
combined with AMF in delivering hyperthermia treatment 
to tumors. Although hyperthermia produced by SPIONs 
after direct injection has shown potential for tumor ablation, 
this technique is only deliverable to superficial tumors and 
is unlikely to supersede the therapies that are in effect at 
the moment. However, MSCs have the potential to deliver 
SPIONs to tumors deep within the body at metastatic sites.
In our studies, we have demonstrated that the size and 
chemical coating of the SPIONs influence human MSC 
uptake in a similar manner to that we had previously seen 
Figure 2 Murine model of OVcar-3 tumor growth, with and without magnetic heating.
Notes: (A) experimental plan of MrI and aMF heating. (B) T2 weighted Mr images of a heated and nonheated OVcar-3 tumor coinjected with Ferucarbotran-labeled 
Mscs, at days 14 (prior to heating), 18, and 22 (postheating) (white arrow indicates signal recovery). (C) Thermocamera image of a heated tumor (T) on the flank of a nude 
mouse (F) with C indicating the MACH coil and P the fiber-optic thermometry probe. (D) Fiber-optic thermometry measurements of a heated tumor over days 15, 17, 19, 
and 21 and a representative nonheated tumor and core body temperature. (E) Post-innoculation OVcar-3 tumor growth for both heated and nonheated tumors.
Abbreviations: MRI, magnetic resonance imaging; AMF, alternating magnetic field; MR, magnetic resonance; MACH, magnetic alternating current hyperthermia; sec, 
seconds; Mscs, mesenchymal stem cells.
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for rabbit MSCs.31 The greater uptake of FluidMAG-CT is 
most likely due to the increased number of carboxyl groups 
and the subsequent greater charge on the particle surface.37,38 
However, despite its relatively low concentration after cell 
internalization (60 pg/cell compared to 250 pg/cell), it was 
Ferucarbotran, originally an MRI liver contrast agent,39 that 
exhibited the best heating characteristics. This is a reassuring 
result, given that Ferucarbotran has recently been used in a 
number of other hyperthermia studies.40,43,44
The observed in vitro temperature rise of 5.9°C from 
baseline using Ferucarbotran in a cell pellet was not quite 
matched in the tumor model, where the surface temperature 
rise was more moderate at 4.3°C – albeit the internal tem-
perature may have been higher. No significant hot spots were 
shown on the thermocamera, which showed a near-uniform 
temperature increase across the whole tumor, although 
histology suggested that the SPIO-loaded MSCs were not 
heterogeneously spread throughout the tumor tissue.
Although somewhat beyond the intended scope of the 
present study, it is interesting to examine the physiologi-
cal outcomes of AMF treatments on the mice. Despite the 
4.3°C rise in surface temperature, the hyperthermia treatment 
Figure 3 Immunohistochemistry data from a human OVcar-3 tumor model, with and without magnetic heating.
Notes: (A) sections from a representative tumor stained with DiI cell tracker dye, Perl’s Prussian blue iron stain, and h&e on day 22, derived from a coinjection, on day 1, of 
Ferucarbotran-labeled Mscs and OVcar-3 tumor cells that were subsequently either heated or nonheated. (B) Percentage stained areas of representative slices throughout 
both heated and nonheated tumors for both Perl’s and DiI staining (error bars are seM and **P,0.01).
Abbreviations: h&e, hematoxylin and eosin; Mscs, mesenchymal stem cells; seM, standard error of the mean.
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did not result in measurable retardation of tumor growth. 
A possible explanation for this is that the overall MSC 
and SPION concentration was simply not enough to cause 
large-scale tumor cell death. A contributing factor here could 
have been the increase in tumor volume causing an already 
inhomogeneous distribution of MSC to be further dispersed, 
thereby reducing the local concentration of SPIONs. Another 
possibility is that the initial heating was effective enough to 
induce destruction of the MSC population and loss of the 
SPIONs, but not widespread enough to retard the prolifera-
tion of OVCAR-3 cells during the fast-growth phase. In any 
case, it was difficult to assess any local increase in necrosis 
that may have been caused, given the inherently high base-
line necrosis of the tumor model and the small number of 
animals used.
Nevertheless, both MRI at day 22 and subsequent histol-
ogy sections showed reduced iron and DiI staining in the 
AMF samples, suggesting heating-induced MSC death with 
subsequent clearance of both SPIONs and MSCs, compared 
to that in the nonheated tumors. At the same time, there were 
still some single MSCs remaining after four heating treat-
ments. Histology showed that these remaining MSCs were 
surrounded by cancer cells. Given the previously observed 
inhomogeneity in the distribution of MSCs in the nonheated 
tumors, this might be an indication that cell death and 
removal were predominantly affected in the MSC clusters, 
rather than in isolated MSCs. If this were the case, it would 
appear that to promote intracellular heating, and therefore 
improve prospects of killing adjacent cancer cells, it may be 
important to find ways to promote the clustering or aggrega-
tion of magnetically labeled cells at the target tumor site.
MRI was found to be a good way of evaluating MSC 
death. Dead MSCs and exogenous SPIONs are cleared by 
tumor macrophages leading to changes in SPION concentra-
tion and distribution within tumors, with areas of MRI signal 
recovery correlating well with areas of low Perl’s Prussian 
blue and DiI staining by histology in hyperthermia-treated 
tumors. However, the retention of the MRI signal loss in 
the nonheated tumors suggests that we can label MSCs with 
iron for at least 2 weeks, that they are viable (otherwise, 
they would have been cleared), and that they are retained 
within the tumor tissue over this time. The fact that we also 
show tumor heating of up to 4.3°C at day 14 indicates that 
Ferucarbotran retains its heating properties over this period 
and is not degraded within the cells.
Although we have not replicated the near or complete 
regression of tumors shown in studies using direct injection 
of SPIONs,6–8 the effects we have seen were with 
concentrations that were several-fold less. Furthermore, 
the absence of any immune response in our mouse model 
may be significant. A recent study by Basel et al45 evaluated 
mouse monocyte/macrophage-like cells as iron carriers 
that migrate toward disseminated peritoneal pancreatic 
cancer cells after intraperitoneal injection. They showed an 
increase in survival time in the AMF-treated mice compared 
to controls, using a combination of cell labeling and AMF 
characteristics that resulted in an overall tumor heating 
of 4°C – similar to that observed in this study. Basel et al 
explained their result partly on the basis of recruitment of 
various immune cells to the tumors.46–49 Hyperthermia causes 
the expression of HSPs that in turn induces antitumor immu-
nity, activating antigen-presenting cells to migrate into and 
kill both heated and nonheated tumors, including metastatic 
disease.50–53 However, in this study, histology staining for 
HSP70 was inconclusive, which may be due to the fact that 
the highest temperature increase occurred at the first AMF 
treatment. As HSP70 expression is transient, this would 
decrease over the subsequent AMF treatments and may 
have fully recovered prior to tissue removal.42 We therefore 
surmise that it is possible that we are heating to temperatures 
capable of triggering an immune response but that, by using 
human cancer cells in an immunodeficient mouse, we are 
observing only the pure effect of heating and therefore do 
not gain from the immunogenic effect.
It therefore appears to be the case that the immune system 
has a much larger role to play in tumor cell death than from 
direct hyperthermia than previously thought. Nonetheless, 
our human MSCs are more efficient iron carriers than the 
mouse monocyte-/macrophage-like cells used in the study by 
Basel et al, as they showed no iron breakdown and retained 
efficient heating qualities for .2 weeks after injection, 
allowing for a long time window for AMF treatments in 
patients; however, phagocytic cells metabolize iron within 
days. Therefore, further studies using mouse MSCs in an 
immunocompetent mouse model would greatly benefit this 
AMF treatment approach.
Looking ahead, it is interesting to speculate that AMF 
treatments may find a role in the treatment of metastatic 
cancers that is not based on thermoablation and cellular 
necrosis, but rather on moderate levels of hyperthermia, 
leading to individual-cell apoptosis and instigation of the 
body’s own immune response. Recent results from our own 
laboratory show the ability of hyperthermia to elicit cell-
by-cell controlled apoptosis,54 and studies by Ito et al51,52 
and Sato et al55 suggest that even local hyperthermia could 
induce a form of vaccination that may be effective against 
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metastatic disease, negating the need for the distribution of 
MSCs throughout whole tumor tissues. As such, we may, in 
the future, be looking to magnetic field hyperthermia as an 
adjuvant, rather than an intervention in its own right.
Conclusion
In summary, although we have by necessity been restricted 
to a limited number of small animal experiments, we have 
nevertheless demonstrated in vivo that MSCs can be used as 
carriers of Ferucarbotran SPIONs, that these labeled MSCs 
can remain viable and can be retained in the tumor tissue 
over a matter of weeks, and, that in that time, the internal-
ized Ferucarbotran can remain intact and preserve its heating 
capacity within the cell.
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